Fundraising FoxArialys
La Jolla, US · Founded 2021 · Delaware corporation · 3 known investors
Find your way into Arialys
Sign up to see every warm intro you have to Arialys
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Arialys team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Arialys Therapeutics develops precision medicines designed to block pathogenic autoantibodies that target brain receptors such as the NMDA receptor, aiming to treat neuropsychiatric disorders driven by autoimmune disease. It focuses on autoimmune neuropsychiatry, addressing conditions including encephalitis, schizophrenia, dementia, and cancer-related cognitive impairment.
Founders & leadership
PF
Peter Flynn, Ph.D.Executive
Board
JL
Jay Lichter, Ph.D.Board director
BS
Brian Slingsby, M.D., Ph.D., M.P.H.Board director
EH
AX
Ashish Xavier, Ph.D.Board director
TR
Investors · 3
Reported raises · per SEC filings
Form D private placements$29.1M disclosed across 2 of 3 rounds · 2022–2025
▶$14.8MraisedJul 2025 · 7 investors · BiotechnologyRule 506(b)
▶$14.8MraisedJul 2025 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jay Lichter, Ph.D.Director
- Peter Flynn, Ph.D.Executive Officer, Director
- Brian Slingsby, M.D., Ph.D., M.P.H.Director
- Ed HurwitzDirector
- Ashish Xavier, Ph.D.Director
- Offering amount
- $24.8M
- Amount sold
- $14.8M
- First sale
- Jun 2025
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$14.3MraisedDec 2022 · 6 investors · BiotechnologyRule 506(b)
▶$14.3MraisedDec 2022 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jay Lichter, Ph.D.Executive Officer, Director
- Ed HurwitzDirector
- Brian Slingsby, M.D., Ph.D., M.P.H.Director
- Tighe ReardonExecutive Officer
- Offering amount
- $55M
- Amount sold
- $14.3M
- First sale
- Nov 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 9
Eli LillyEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.
Mineralys TherapeuticsMineralys Therapeutics is a clinical-stage pharmaceutical company developing lorundrostat, a treatment targeting dysregulated aldosterone. It focuses on cardio-renal-metabolic diseases, including hypertension and chronic kidney disease.
Altay TherapeuticsAltay Therapeutics develops small molecule inhibitors targeting transcription factors to treat serious diseases including facioscapulohumeral muscular dystrophy and cancer. The company's pipeline includes oral drug candidates designed as first- or best-in-class therapeutics for oncology and inflammatory conditions.
CrystalystxCrystalys Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapies for gout, a chronic metabolic disease caused by elevated uric acid. Its lead investigational therapy is a selective URAT1 inhibitor designed to lower serum uric acid by targeting renal urate reabsorption pathways.
ExelixisExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
AlumisAlumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases. It focuses on small-molecule drug discovery and development in immunology and inflammation.
AmylyxAmylyx is a biopharmaceutical company developing novel therapies for diseases with high unmet medical needs. It focuses on solving difficult medical challenges for affected patients and their families.
AlloyAlloy provides drug discovery services and platform technologies across genetic medicines, TCR mimics, and cell therapies, supporting pharmaceutical partners in developing novel treatments.
Companies working in the same space as Arialys.
In the news
Frequently asked questions
- What does Arialys do?
- Arialys Therapeutics develops precision medicines designed to block pathogenic autoantibodies that target brain receptors such as the NMDA receptor, aiming to treat neuropsychiatric disorders driven by autoimmune disease. It focuses on autoimmune neuropsychiatry, addressing conditions including encephalitis, schizophrenia, dementia, and cancer-related cognitive impairment.
- Who are Arialys's investors?
- Arialys's investors include Avalon BioVentures, Catalys Pacific, MPM BioImpact.
- How much funding has Arialys raised?
- Arialys has disclosed $29.1M raised across 2 of its 3 known rounds.
- Where is Arialys headquartered?
- Arialys is headquartered in La Jolla, US.